R&D channel feed

Karyopharm shares tank af­ter FDA in­sid­ers slam their case on the ef­fi­ca­cy of a can­cer drug with “sig­nif­i­cant tox­i­c­i­ty”

7 years ago
Pharma

Ab­b­Vie hands Voy­ager a mega-bil­lions gene ther­a­py deal, with $310M in near-term cash

7 years ago
Pharma

Nar­can mak­er Opi­ant shelves bu­lim­ia pro­gram af­ter mid-stage flop

7 years ago

J&J steps up along­side Ab­b­Vie to part­ner with fast-grow­ing Mor­phic on its small mol­e­cule ap­proach to in­te­grins

7 years ago
Pharma

Deaths spur par­tial hold for Xen­cor’s CD3 bis­pe­cif­ic for leukemia, part­nered with No­var­tis in $2.5B deal

7 years ago

Stem cell ther­a­pies for space mis­sions? Pluris­tem joins forces with NASA to com­bat space-re­lat­ed ail­ments

7 years ago
Pharma
Cell/Gene Tx

Pfiz­er drops 10 mg dose of best-sell­ing Xel­janz as study spot­lights car­dio safe­ty is­sue, high­er rate of deaths

7 years ago

Mer­ck’s PhI­II liv­er can­cer study for Keytru­da fails on two key end­points, just three months af­ter the FDA gave it the green light

7 years ago

Strike 3: Vi­cal ax­es its on­ly re­main­ing clin­i­cal pro­gram, com­plet­ing a tri­fec­ta of dis­as­ters

7 years ago

Is­rael's Im­mune Phar­ma waves the white flag af­ter fail­ing to se­cure deals for in­flam­ma­tion drug

7 years ago

In­ter­cept scores a mixed win on NASH Phase III sweep­stakes, plans mar­ket­ing pitch

7 years ago

Dogged by safe­ty is­sues, Eli Lil­ly and Pfiz­er tout their lat­est PhI­II for an­ti-NGF pain drug tanezum­ab

7 years ago

Throw­ing in the tow­el, trou­bled an­tibi­ot­ic mak­er Ar­a­digm files for Chap­ter 11

7 years ago

In a pi­o­neer­ing re­gen­er­a­tive med study, sci­en­tists get a green light to test iPS cells for spinal cord dam­age

7 years ago

French biotech In­ven­ti­va's lead drug stum­bles in sys­temic scle­ro­sis study, ahead of NASH read­out

7 years ago

Bay­er, Ori­on prostate can­cer drug cuts risk of metas­ta­sis or death by more than 50% in key study

7 years ago

The top 10 pipeline blowups, set­backs and sna­fus for H2 2018

7 years ago
Special

In­di­a's gener­ic drug mak­er Glen­mark draws up a US-based brand­ed drugs unit

7 years ago

An­tipsy­chot­ic from Lund­beck, Ot­su­ka flops again in PhI­II tri­als — this time in bipo­lar pa­tients

7 years ago

Mo­tif Bio's turn­around quest for once-re­ject­ed an­tibi­ot­ic hits the CRL wall

7 years ago

As­traZeneca drops an OX40 can­cer drug can­di­date in Q4 pipeline cleanup

7 years ago

As­traZeneca sweeps away the Med­Im­mune name as CEO So­ri­ot re­struc­tures R&D

7 years ago

Affini­vax, Astel­las be­gin clin­i­cal quest to beat Pfiz­er's Go­liath with a new kind of pneu­mo­coc­cal vac­cine

7 years ago

In the bat­tle against kid­ney can­cer, Mer­ck­'s key­stone im­munother­a­py Keytru­da edges in front

7 years ago
First page Previous page 252253254255256257258 Next page Last page
A service from the Financial Times